Chronic pulmonary aspergillosis
aspergilloma / CPA · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic pulmonary aspergillosis is a slowly progressive Aspergillus infection in patients with pre-existing lung cavities or damage (prior TB, NTM, sarcoid, COPD). It ranges from a simple aspergilloma to chronic cavitary and fibrosing disease and is distinct from ABPA and invasive aspergillosis.
Red flags
- Massive haemoptysis
- Rapid cavity enlargement or systemic deterioration (consider invasive disease)
- Significant weight loss and cachexia
- Azole hepatotoxicity or QT prolongation
Assessment
Differential diagnosis
- Reactivation tuberculosis
- Non-tuberculous mycobacterial disease
- Lung cancer
- ABPA
- Invasive aspergillosis
- Chronic bacterial infection
Investigations
- CT chest (cavity with fungal ball/mycetoma, pleural thickening, progressive cavitation)
- Aspergillus-specific IgG (precipitins) — key serological test
- Sputum/BAL culture and Aspergillus PCR, galactomannan
- Exclude active TB (AFB, culture)
- Spirometry and nutritional assessment
- Inflammatory markers to monitor activity
Management
- Suspect in chronic respiratory symptoms with cavitary lung disease and weight loss
- Confirm with Aspergillus IgG positivity plus compatible imaging over >=3 months
- Exclude active TB and malignancy as alternative causes
- Classify: simple aspergilloma vs chronic cavitary/fibrosing aspergillosis
- Treat symptomatic or progressive disease with long-term oral azole therapy
- Monitor azole levels, LFTs, QTc and drug interactions
- Reserve intravenous/alternative antifungals for azole failure or resistance
- Consider surgical resection for localised disease or life-threatening haemoptysis in fit patients
- Use bronchial artery embolisation for significant haemoptysis
- Monitor long term with imaging, IgG trends and symptom/weight assessment
Drugs & doses
Itraconazole 200 mg PO twice daily (with level monitoring)
Voriconazole 200 mg PO twice daily (alternative/first-line, monitor levels)
Posaconazole 300 mg PO once daily (after loading) for azole intolerance/resistance
Liposomal amphotericin B / micafungin IV for severe azole-refractory disease
Disposition
Specialist respiratory / national aspergillosis service; thoracic surgery and interventional radiology for haemoptysis; long-term monitoring.
Complications & pitfalls
- Life-threatening haemoptysis
- Progressive pulmonary fibrosis and respiratory failure
- Azole toxicity and resistance
- Secondary bacterial infection
Exam pearls
- Aspergillus IgG (precipitins) is the single most useful diagnostic test for CPA
- A simple aspergilloma in a single cavity may be managed with observation or surgery rather than lifelong azoles
- Bronchial artery embolisation controls haemoptysis but is often a temporising measure
- Azole resistance is rising — check levels and susceptibilities in non-responders
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.